Area:
Neuroscience Biology
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Daniel J. Schuster is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2009 — 2011 |
Schuster, Daniel J. |
F31Activity Code Description: To provide predoctoral individuals with supervised research training in specified health and health-related areas leading toward the research degree (e.g., Ph.D.). |
Gene Therapy in Chronic Pain @ University of Minnesota
DESCRIPTION (provided by applicant): Opioid receptors are expressed by small diameter nociceptive afferent fibers. Augmenting their expression by viral transduction may enhance the power of opioid agonists to inhibit the neurotransmission of pain signals to secondary spinal cord neurons. The adeno-associated virus (AAV) serotype has been shown to be useful for transduction of neurons in cortex, brainstem, and cerebellum. Its utility for transduction of neurons in the spinal cord and dorsal root ganglia (DRG) has also been explored with limited success due to meningeal barrier limitations. Our application of a hyperosmotic agent as a pre-treatment has resulted in significant gene transfer to the spinal cord and dorsal root ganglion neurons. The proposed research will assess the utility of delivery of AAV- vector by lumbar puncture as a useful tool for basic scientific study of chronic pain as well as a potential therapeutic delivery option. The primary objectives of the project are: 1) Validate efficacy of intrathecally administered AAV5 for delivery of target genes to the spinal cord and DRG neurons anatomically and neurochemically. 2) Validate antinociceptive functionality of genes transferred by intrathecal delivery of AAV5 vector to spinal cord and DRG neurons. The proposed fellowship, focused on neuropathic pain, will proceed in context with parallel studies involving opioid tolerance and self-administration. Gene therapy using viral vectors may permanently alter the molecules produced by neurons. This project seeks to augment the availability of opioid receptors to prevent or correct maladaptive changes.
|
1 |